A Review of Osteosarcoma Therapeutics

Michael W. Beaury1, Megan L. Kelly-Beaury2, Gilbert Sharp3, Jessica A. Cottrell4*

Seton Hall University, South Orange, NJ, USA


Osteosarcoma is a rare but deadly cancer, predominantly affecting both adolescent and young adult populations. Osteosarcoma occurs when an aggressive malignant neoplasm arises from transformed cells of mesenchymal origin, which eventually produce a malignancy in the osteoid. Diagnosis of osteosarcoma typically results from symptoms of pain or swelling in the bone, which can be confirmed through laboratory testing of alkaline phosphatase and lactate dehydrogenase levels as well the detection of microscopic and macroscopic lesions. Pathogenesis of osteosarcoma is caused by a diverse set of factors including physical agents, radiation, chromosomal aberrations and viral infection which dysregulate cellular functions. Current research focuses on understanding how microRNAs play a role in osteosarcoma and other aggressive cancers. In this review, we discuss current treatments options including chemoresistant strategies and immunotherapies that show promise at combating osteosarcoma and other cancers.


Osteosarcoma is a low incidence or uncommon cancer, which originates in the bones and is predominantly found in adolescents and young adults. Osteosarcoma usually occurs in individuals in the range of 10 to 30 years of age, although teens are the most commonly affected. Each year, 1,000 cases of osteosarcoma are diagnosed in the United States, and 45% of those cases occur in children and adolescents. Approximately seventy percent of patients with non-metastatic osteosarcoma can survive long-term with multidrug chemotherapy1. However, patients with metastatic osteosarcoma rapidly development lesions and become resistant to chemotherapy. The development of secondary tumors in these patients is a common cause of morbidity1. New therapies for metastatic osteosarcoma are needed to help prevent morbidity in these patients. Below we review current mechanisms of pathogenesis, diagnosis, and treatment strategies including chemoresistant therapies, immunotherapies, and microRNA derived techniques.

Numerous factors have been associated with osteosarcoma pathogenesis including age, gender, environmental agents, genetic background, and viral infection. Rapidly growing bones, especially during puberty, are an easy site for osteosarcoma tumorigenesis2. Physical agents, ultraviolet light, and ionizing radiation are agents known to cause osteosarcoma in 2% of all cases but have not been demonstrated to have a large effect in pediatric cases3.

Methylcholanthrene, chromium salts, beryllium oxide, zinc beryllium silicate, asbestos, and aniline dyes are chemical agents known to cause osteosarcoma. Chromium salts, with or without methylcholanthrene treatment, can transform non-tumorigenic osteoblast-like human osteosarcoma cells. Although the chromium salts alone were highly toxic to the cells, the cells that survived had a marked increase in anchorage independent growth when compared to controls. Cells treated with chromium salts and methylcholanthrene together had an even larger rate of anchorage independent growth. The cells themselves were not tumorigenic when tested in nude mice, but had altered phenotypes that demonstrated hallmarks of a stage in the carcinogenesis cascade4. Beryllium oxide and calcined phosphor were shown to induce osteosarcoma as well as other neoplastic growths in a rabbit model. Rabbits were injected three times a week for six to eight weeks. Osteosarcomas developed in 6 of the 9 animals that lived over 1 year and the first tumor appeared 11.5 months after the start of the experiment. The data demonstrate that beryllium compounds not only induced osteosarcoma, but also metastatic tumors of the lung, liver, spleen, kidney, heart, and urinary tract. Earlier studies support this data demonstrating that injection of beryllium compounds induced osteosarcoma in the epiphysis, tibial, scapula, and femoral in mammals such as guinea pigs and rabbits5, 6.

Genetic changes such as chromosomal abnormalities or mutations in tumor suppressor genes and proto-oncogenes can also contribute to the onset of osteosarcoma. Chromosomal abnormalities in patients with Bloom syndrome, Rothmund-Thompson syndrome, Werner syndrome, Li-Fraumeni syndrome, and hereditary retinoblastoma often have a higher risk of developing multiple malignancies such as osteosarcoma7. Osteosarcoma has also been linked to amplification of chromosomes 6p21, 8q24, an 12q14, loss of heterozygous chromosome a 10q21.1, and changes in chromosomes 9, 10, 13, and 178.

The mutated forms of tumor suppressor genes p53 and retinoblastoma (Rb) lose their functions and are associated with various cancers. p53 and Rb genes are known to repair DNA damage or induce cell apoptosis7, 9. If they become mutated, these protective functions are compromised and can allow the cell to become neoplastic. Both of these genes have been indicated in the pathogenesis of osteosarcoma7, 9. Fifty percent of all cancers have a mutated p53 gene; this gene is also mutated in 22% of osteosarcomas, showing the importance of this gene mutation in cancer’s progression7, 9. Rb is important in cell cycle regulation by binding transcription factors of the E2F family until CDK4/cyclin D complex phosphorylation occurs. Mutation in Rb allows for E2Fs to allow the cell cycle to continue without regulation10 An individual with Li-Fraumeni syndrome has a 70% chance of developing primary invasive cancer, including osteosarcoma but excluding skin cancer11.

Proto-oncogenes such as c-fos, c-jun, myelocytomatosis proto-oncogene protein (c-myc) have been associated with osteosarcoma. Activator protein 1 complex (AP-1) is a heterodimeric complex composed of c-fos and c-jun. AP-1 controls bone metabolism, cell proliferation, and differentiation, whereas c-myc stimulates growth and division in the nucleus. Analysis of primary skeleton neoplasms via immunohistochemistry found c-fos and c-jun expression in bone-forming lesions. Further analysis demonstrated that high-grade osteosarcomas had elevated levels of c-fos and c-jun12 associating their expression with aggressive human osteosarcoma. Wu et al.’s data demonstrate that c-fos expression is elevated 150% in human osteosarcoma sections when compared to benign or normal tissues. Further supporting the conclusion, that c-fos is involved in the growth and spread of osteosarcoma tumor formation13. In another study using osteosarcoma and lung metastases, c-myc and c-fos gene and protein expression was significantly elevated in relapsed tumors and was correlated with metastasis frequency and intensity14. Myc overexpression has also been correlated with osteosarcoma pathogenesis and chemotherapeutic resistance. Shimizu et al. demonstrated that overexpression of c-myc in bone marrow stromal cells derived from Ink4a/Arf null mice could generate lethal osteosarcoma cells15. In a different murine osteosarcoma study, TAM67 was used to conditionally inhibit AP-1 activity in highly metastatic K7M2 cells. AP-1 inhibition blocked the migration and invasion potential of these cells and increased mouse survival suggesting that AP-1 inhibition could be used a therapeutic tool to prevent invasion, metastasis, and migration of osteosarcoma tumors16.

Patients diagnosed with osteosarcoma will normally present with pain and swelling in the metaphyseal bone of the distal femur, proximal tibia, and proximal humerus; blunt force trauma to those regions have also been noted before diagnosis, although a scientific link to trauma and osteosarcoma is unknown. Pain is typically associated with activity and overtime the pain occurs during restful periods and is also attributed to growing pains in children. In a study involving osteosarcoma symptoms, pain in the knee joint was always the first reported and was more intense when bearing weight and at night. Two-thirds of patients had a limp, and only seven percent of patients had a pathological fracture. Among these patients, the study identified that the mean total delay for diagnosis was 17 weeks17.

Noninvasive diagnostics methods have improved detection over the past decades and includes the use of radiography, computed tomography (CT), magnetic resonance imagining (MRI), positron emission tomography (PET) or a combination of these methods. Radiographs typically detect lesions with defects including osteolytic areas, periosteal reactions, or the development of soft tissue masses7. CT scans are utilized at defining fracture sites or irregularities in mineralization, the cortices, or neurovascular development7. Often MRIs are employed to assess soft tissue invasion, neurovascular damage, bordering joint damage, or to determine bone marrow replacement needs7. Ongoing research is being conducted to determine ways PET can be used to determine metabolic rates of osteosarcoma, the response rate of neoadjuvant therapy and other post treatment changes which is thoroughly reviewed by Brennan et al18. Still, biopsy and microscopic examination are required to confirm the diagnosis. These examinations carry additional prognostic implications such as subtype classification and histological response to neoadjuvant chemotherapy19. Osteosarcoma subtypes can be divided into many groups including conventional osteosarcoma (subdivided into osteoblastic, chondroblastic or fibroblastic groups), telangiectatic, small-cell, low-grade, parosteal, periosteal, and high-grade surface osteosarcomas. These subtypes are classified based upon their histological appearances19.

No official laboratory test exists as a diagnosis for OS. However, basic lab tests such as complete blood count, metabolic panels, and other functional tests can be useful pretreatment to assess a patients help before the onset of chemotherapy. Laboratory testing has shown that alkaline phosphatase levels can be elevated in osteosarcoma patients by approximately 40%. When patients had elevated levels of the alkaline phosphatase enzyme in the preoperative stage, their recurrence rate is found to be much higher, and they have a poorer prognosis20. Lactate dehydrogenase levels can also be elevated in osteosarcoma patients. In a multi-institutional osteosarcoma study, elevated lactate dehydrogenase (LDH) levels were found to be the most predictive factor for a poorer prognosis21. In another study that correlated LDH levels and prognostic value, researchers found that metastatic patients had a significantly higher level of LDH than patients who only had localized osteosarcoma22. It is still unclear whether lactate dehydrogenase and alkaline phosphatase should be used as indicators for osteosarcoma, however approximately 80% of patients present with microscopic metastatic disease or have undetectable patterns. Therefore, utilizing LDH and alkaline phosphatase levels as indicators of osteosarcoma maybe useful in early stages or in conjugation with other diagnostic measures.

Following clinical presentation and diagnosis, the next step is the treatment to remove and potentially eradicate the tumors. Surgery is commonly the first step in treatment and can include removal of just the tumor or potentially the limb itself. Surgical treatment requires the complete removal of the affected tissue including areas where biopsies occurred, drainage, and other potentially contaminated tissue. Chemotherapy following surgery is the next step to ensure eradication, although chemotherapy can be given before and after in some cases. Early chemotherapeutic agents bleomycin, cyclophosphamide, and actinomycin D were frequently used, but now doxorubicin and methotrexate are now more commonly used. Clinical trials relating to many osteosarcoma treatments have been completed or actively ongoing23-25. A host of chemoresistant strategies, immunotherapies, and microRNA-derived techniques have been developed to help improve patient outcomes and is reviewed below.

Gene expression is often altered in osteosarcomas so that the tumor cells can continue to proliferate despite chemotherapeutic treatments. Downregulation of reduced folate carriers (RFCs) are often observed in chemoresistant osteosarcomas. RFCs are located at the cell membrane and are utilized by chemotherapeutics like methotrexate to enter the cytoplasm of the cell26. Mutations seen in the RFC protein sequence include Leu291Pro, Ser46Asn, Ser4Pro, and Gly259Trp and prevent chemoresistant treatments from entering tumor cells27-29. These mutations alter the structure of the enzyme so that drugs like methotrexate cannot associate with the protein and enter the cell membrane27. An alternative to methotrexate is trimetrexate, a drug that has a similar chemotherapeutic function, but does not utilize RFC to enter the cell30. Limited clinical studies exist using trimetrexate31 but transport defective tumor cells are sometimes more sensitive to this drug32. Therefore, trimetrexate is a potential candidate to overcome the methotrexate transport resistance33. Another cellular enzyme that prevents drugs from remaining in tumor cells is the P-glycoprotein pump (P-GP). The transcription factor, MDR1 (multidrug-resistant gene) can upregulate P-GP in chemoresistant tumor cells and promote the removal of chemotherapeutic drugs like doxorubicin from the cytoplasm of the cell34, 35. To overcome P-GP expression in tumor cells, doxorubicin is delivered to cancerous tissue along with a silencing RNA (siRNA) sequence via a nanoparticle vector. The specific siRNA is modified within the cell to miRNA, which blocks the expression of P-GP allowing doxorubicin to complete its function36.

Other genes are often directly upregulated in osteosarcoma tissues to directly combat the presence of chemotherapeutic drugs. Glutathione S-transferase P1 (GTSP1), an enzyme that has detoxifying characteristics, inactivates various types of treatments and is often overexpressed in osteosarcoma37, 38. Osteosarcoma patients with mutant variants of the GTSP1 protein have shown increased resistance to several therapeutic drugs including methotrexate, adriamycin and cisplatin39. To combat GSTP1-based resistance, an inhibitor of GTSP1, NBDHEX was developed. In vitro studies have observed that NBDHEX does not increase apoptosis in tumor cells but does prevent metastatic signaling40.

Signaling pathways for cell proliferation and anti-apoptotic factors become overactive in several tumor cells including osteosarcoma. Chemotherapeutic drugs like rapamycin, cisplatin and doxorubicin that have inhibited these pathways in the past are now obsolete41-43. New treatment strategies and pharmaceuticals are being developed to improve these key treatment types44, 45. For instance, rapamycin and its analog molecule, cell cycle inhibitor-779, are used in tandem in one treatment that has led to significant inhibition of the mammalian target of rapamycin (mTOR) pathway1, 46. Doxorubicin treatment together with the insulin-like growth factor receptor 1 (IGF-R1) inhibitor, tyrphostin, increases cellular apoptosis much better than doxorubicin treatment on its own45. New treatments cediranib and trastuzumab were generated to specifically target vascular endothelial growth factor (VEGF) and human epidermal growth factor receptor 2 (HER2) respectively, resulting in inhibition of tumor growth47, 48. Advances in genetic manipulation within the genome of a lentivirus can generate an abundance of short-hairpin RNA (shRNA), miRNA and cDNA sequences to knockdown specific gene expression, such as IGF-R1, BCL-2 and BCL-xL, that allows for increased sensitivity to doxorubicin and cisplatin43, 49, 50. Autophagy is a process that occurs in cells under harsh conditions where the cells’ organelles and proteins are degraded but prevents the cell from undergoing apoptosis. This process is observed frequently in tumor cells and promotes chemo-resistant characteristics, as observed in osteosarcoma cell lines treated with doxorubicin and roscovitine51, 52. Several treatments have been developed to push cancerous cells into apoptotic processes from the autophagy state. In several in vitro studies, the use of autophagy inhibitors chloroquine and 3-methyoadenine (3-MA) treated simultaneously with 5-fluorouracil, paclitaxel (PCX) and cisplatin increased apoptotic events in known autophagy osteosarcoma cells53-55.

Chemotherapeutic resistance has led to the development of new strategies in immunotherapuetics. Immunomodulation, adoptive T-cell immunotherapy, vaccines, immunologic checkpoint blockade, oncolytic virotherapy and targeted therapies have been developed. Immunomodulation adjusts the immune system in a way to target the cancer itself. For example, a synthetic lipophilic analogue of muramyl dipeptide, muramyl tripeptide phophatidylethanolamine (MTP-PE), has been encapsulated into liposomes (L-MTP-PE) as a way for targeted therapy to allow monocytes and macrophages to induce tumoricidal qualities1, 46. Tumoricidal qualities help immune cells release factors such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β). The release of these proinflammatory factors promotes the removal of residual micrometatases not eliminated with surgery and chemotherapy. Induction of tumoricidal activity by macrophages induced with L-MTE-PE may be dependent on interferon-γ (IFN-γ), which enhances the liposome intake of the macrophage.

Interferons are pleiotropic cytokines that are involved in antitumor, antiangiogenic, apoptotic, antiviral, and cellular immune responses. Three subtypes of IFN, IFN-α, IFN-β, and IFN-γ, which have direct and indirect activation of T-cells and B-cells56. IFN-α has been shown to inhibit osteosarcoma growth and arrest growth of tumors, therefore it is commonly used as the IFN treatment of choice46. A small study of three patients with osteosarcoma related pulmonary metastases underwent treatment with human leukocyte interferon. Treatment reduced the tumor size temporarily 6-8 months after administration57. In a phase two clinical trial with 20 patients suffering from high-grade osteosarcomas, IFN-α2a treatment only caused partial tumor regression in three patients58. Granulocyte macrophage-colony stimulating factor (GM-CSF) has also been shown to induce differentiation and apoptosis of osteosarcoma cells. In this study, treatment of SaOS-2 human osteosarcoma cell line with GM-CSF daily promoted the differentiation and function of these cells including extracellular matrix mineralization and collagen production. However, fourteen days post GM-CSF treatment, the SaOS-2 cell line was found to have high levels of apoptotic cell death when compared with the controls via flow cytometry59. Interleukin-2 (IL-2) has been added to standard treatments to help increase the prognosis of patients with osteosarcoma. IL-2 can stimulate and upregulate T-cells and natural killer (NK) cells to activate lymphocytes to become lymphocyte-activated killer cells (LAK). LAK cells have the ability to target and kill tumor cells. Studies show that IL-2 treatment with complete surgical remission and can prevent recurrence and increase survival rate. This therapy has been shown to significantly increase white blood cells, decrease alkaline phosphatase, but can cause influenza-like symptoms and high fever. Despite these reversible severe side effects, heavily treated pediatric patients have a 50% better prognosis60.

Adoptive T-cell therapy (ACT) uses T-lymphocytes exhibiting antitumor activity to mediate responses. Genetic engineering of T-cells, T-cell receptor (TCR)-modified T-cells, chimeric antigen receptor (CAR)-modified T-cells, and NK cells, have shown promise to target tumor cells and have been extensively reviewed and therefore are briefly summarized below61, 62. T-lymphocytes that have been removed from a patient, expanded in vitro, genetically engineered and reintroduced into the patient have been found to be very effective at tumor regression. Genes for TCRs can be cloned into lentiviruses or retroviruses and use for infection of autologous T-cells. Synthetic receptors with extracellular single-chain variable fragments (scFv) derived from monoclonal antibodies, transmembrane domain, and intracellular domain with differentiation clusters known as CARs can also be used as effective tumor treatment63. CAR T-cells have been developed against human epidermal growth factor receptor 2 (HER-2) and IL-11 receptor alpha (Rα)64, 65. For example, a majority of osteosarcoma patients, express low levels of HER2 in their osteosarcoma cells. As a result, HER2 monoclonal antibodies used to treat tumor cells are ineffective. Ahmed et al. demonstrated that genetic modification of T cells for a specific antigen such as HER-2 can cause regression of established osteosarcoma lesions in a metastaic mouse model64. Though CAR therapies have had serious side effects including severe respiratory distress and death66. NK cells have an important role in tumor surveillance and recognition and can be important to the elimination of tumor cells67. Recently, data demonstrated that the reduction of Killer Immunoglobulin-Like Receptor (KIR) receptor-ligand expression in osteosarcoma cells could increase the susceptibility of tumor cells to NK cell mediated66, 68. Other studies support this data by demonstrating that disrupting interactions of KIR with their ligands on tumor cells in vivo can elicit antitumor response69. Potential treatments of the future might include inducing solidity of tumors or activating NK cells to recognize specific oncogenic features in a similar manner to T-cells, leading to NK destruction of tumors.

Vaccines using tumor-associated factors to induce an antitumor immune response have been in development. Tumor-associated factors include gangliosides, heat shock proteins, autologous dendritic cells, tumor peptides or proteins, and autologous or allogeneic tumor cells70. Adjuvants, IL-2 and GM-CSF, or other immunostimulants can be used in the vaccines to enhance the response70, 71. Immunologic checkpoint blockades, CTL antigen-4 (CTLA-4) and PD-1, are currently being researched in osteosarcoma immunotherapy. CTLA-4 is an immune regulatory molecule for attenuating antitumor responses downstream of T-cell activation. Ipilimumab, a monoclonal antibody, blocks CTLA-4 to enhance antitumor responses by inhibiting regulatory T-cells immunosuppressive capabilities72, 73. PD-1 is part of the CD28 family and is expressed on activated T-cells. When PD-1 and PD-ligand are activated T-cell are stimulated to undergo apoptosis, which contributes to a poor cancer prognosis. Nivolumab is an antibody that blocks PD-1 and can inhibit metastasis, enhance effector T cell function, and increase cytokine production in patients with melanoma, renal-cell cancer, and non-small-cell lung cancer, although its use has been limited in osteosarcoma74-76.

Oncolytic virotherapy is a new treatment approach utilizing replication-competent viruses to selectively infect and damage cancer tissue without the harm to normal tissue77 including osteosarcoma78. Adenoviruses are double stranded DNA (dsDNA) viruses associated with mild respiratory infections, alimentary and conjunctiva infections. Adenoviruses infect cells using receptor-mediated endocytoses, releasing early genes to begin transcription, with these genes binding to Rb and p53 proteins79. Attenuated adenovirus mutants have been shown to be capable of lysing p53-deficient tumor cells but not cells expressing functional tumor suppressor protein p53. Injection of this adenovirus into human cervical carcinomas in a nude mouse model was capable of reducing tumor size80. A phase 1 study using Onyx-15, an adenovirus that targeted p53-deficient cells was well tolerated by patients with head and neck cancer. Five of the 22 patients were found to have some response to therapy and as a result further investigations were necessary81, 82. Another possible oncolytic virus utilized herpes simplex viruses (HSV). HSVs are neurotropic dsDNA viruses with two serotypes, HSV-1 and HSV-2, which infects the mucosa of the mouth, eyes, and anogenital tract83, 84. HSV natural infection causes the host to halt protein synthesis, therefore stopping HSV protein synthesis. The primary neuropathogenicity gene in HSV is γ-34.5 with its protein causing dephosphorylation of eIF-2 thereby removing the inhibition of protein synthesis83, 85. Ras signaling pathway is commonly mutated in cancer, which suppresses the protein kinase (PKR) that inhibits γ-34.5 thereby, allowing HSV to replicate in cancer cells86. ICP-6 is a subunit of ribonucleotide reductase essential in DNA viral replication and is highly expressed in cancer cells. HSV ICP-6 is mutated causing it to only be able to divide in cancer cells and not normal cells. Therefore, a vaccine with HSV having ICP-6/γ-34.5 deletion may allow it to specifically target cancer cells87, 88.

Small non-coding RNA sequences are transcribed from the genomes of animal and plant cells as well as the genetic material of some viral families. Although they do not generate proteins of their own, some of these non-coding sequences are able to regulate protein expression. These sequences are known as microRNA (miRNA). Once transcribed, the pre-miRNA is modified by RNase III enzyme Drosha that forms secondary structures with the RNA sequence before entering the cytoplasm. The double stranded miRNA is then recognized by the RNase III endonuclease known as Dicer, which breaks the secondary structures creating miRNA strands that have the capability of silencing gene expression89. The mature miRNA can either bind directly to a complementary messenger RNA (mRNA) or enter the active site of a ribosome, bind to and prevent movement of the complementary mRNA within. Both mechanisms inhibit protein synthesis of the mRNA and limit gene expression89. This process is a normal occurrence in healthy cells, miRNAs regulate the expression of necessary enzymes and transcription factors that if overexpressed may influence cellular issues. In fact, the study of miRNA over the past two decades has created hypotheses that the development of cancer may be due to irregular expression of miRNA in equal proportion to sporadic mutations of the particular genes90.

Several miRNAs have been observed specifically as chemo-resistant and radiation resistant factors in treating osteosarcoma by targeting tumor suppressor genes that allow apoptosis of the cell, inhibit cell proliferation and migration from the tissue91 . Human apurinic/apyrimidinic (AP) endonuclease APE1 is an endonuclease responsible for repairing DNA damage after exposure to radiation treatment. miRNA-513a-5p is generated to maintain levels of APE1 expression. Osteosarcomas and other aggressive cancers have overexpression of APE1 producing unregulated repair of oncolytic genes as well as downregulation of the miRNA-513a-5p92, 93. Reintroducing miRNA-513a-5p into osteosarcoma cell lines that have reduced expression of APE1 caused cells to undergo apoptosis after DNA damage to radiotherapy92. Natural upregulation of miRNA-224 inhibits Ras-related C3 botulinum toxin substrate 1 (Rac1), a GTPase that when overexpressed in tumor cells is involved in cell proliferation and metastasis. However, overexpression of miRNA-224 creates a negative feedback that allows Rac1 to inhibit the sequences’ production and allow Rac1 to perform its function unhindered by cisplatin treatment94 . Osteosarcoma cell lines can undergo successful apoptosis if treated with exogenous miRNA-224 and cisplatin simultaneously94. Expression of miRNA-138 as well increases tumor sensitivity to cisplatin treatment. EZH2, an inhibitor of the caspase-3 enzyme, is inhibited by miRNA-138, which allows the cell to enter an apoptotic state after chemotherapy treatment95.

Some miRNA sequences are known to increase chemo-resistance of osteosarcoma cell lines. Upregulation of miRNA-21 impedes sprouty homolog 1 (Spry1) and sprouty homolog 2 (Spry2) gene production, important inhibitors of tyrosine kinase receptor signaling from certain growth factors96 . Spry1 and Spry2 function are a major part of cisplatin therapy to reduce tumor characteristics, therefore upregulation of miRNA-21 increases cisplatin resistance of bone tumor and promotes uncontrolled cell proliferation97. Upon treatment with cisplatin and doxorubicin, upregulation of miRNA-140-5p is observed to induce autophagy of the osteosarcoma cell lines and results in cell death98. However, another sequence is upregulated, miRNA-184, after treatment with doxorubicin that increases cell survival by blocking apoptosis inhibitor BCL2L1, contrary to the expression and function of miRNA-140-5p99. miRNA-367 can also prevent apoptosis of cancer cells. miRNA-367 specifically conquers apoptosis through the downregulation of BNIP3L/Nix and the upregulation of BCL-xL100. Other miRNAs that correlate with poor chemotherapeutic remediation in pediatric osteosarcoma include miRNA-221 and miRNA 210101, 102. miRNA-221 prevents expression of NF-κB inhibitors which maintains cell proliferation despite treatments103. miRNA-210 promotes and maintains the initiation of the cell cycle by acting upon E2F3 cell cycle regulator, MNT the myc antagonist and homeobox proteins, despite signals from chemo-therapeutic conditions55, 104, 105. Repressing expression of certain oncolytic miRNA sequences is equally as important as maintaining expression of tumor suppressor genes in other miRNA sequences. This strategy will allow an unhindered chemotherapy treatment to successfully fight against osteosarcoma and other aggressive cancers.

Osteosarcoma is a rare but deadly cancer affecting pediatric patients and in some cases adults. With its rarity, treatment options are limited and require innovative solutions to find effective options, which eradicate tumor cells and tissue without the need for amputation. Emerging treatment options utilize or combine tools harnessed from the host tissue response, chemoresistant therapeutics, immunotherapies, and microRNA therapy to effectively combat and eliminate cancer cells with the ultimate goal of improving patient prognosis and survival rate.

  1. Wan J, Zhang X, Liu T. "Strategies and developments of immunotherapies in osteosarcoma". Oncol Lett. 11: 511-520.
  2. Cotterill SJ, Wright CM, Pearce MS, et al. "Stature of young people with malignant bone tumors", Pediatr Blood Cancer. 2004; 42: 59-63.
  3. Picci P. "Osteosarcoma (osteogenic sarcoma)". Orphanet J Rare Dis. 2007; 2: 6.
  4. Rani AS, Kumar S. "Transformation of non-tumorigenic osteoblast-like human osteosarcoma cells by hexavalent chromates: alteration of morphology, induction of anchorage-independence and proteolytic function". Carcinogenesis. 1992; 13: 2021-7.
  5. Dutra FR, Largent EJ. "Osteosarcoma induced by beryllium oxide". Am J Pathol. 1950; 26: 197-209.
  6. Mazabraud A. "[Experimental production of bone sarcomas in the rabbit by a single local injection of beryllium]". Bull Cancer. 1975; 62: 49-58.
  7. Geller DS, Gorlick R. "Osteosarcoma: a review of diagnosis, management, and treatment strategies". Clin Adv Hematol Oncol. 8: 705-18.
  8. Marina N, Gebhardt M, Teot L, et al. "Biology and therapeutic advances for pediatric osteosarcoma". Oncologist. 2004; 9: 422-41.
  9. Ta HT, Dass CR, Choong PF, et al, "Osteosarcoma treatment: state of the art", Cancer Metastasis Rev 28 (2009): 247-63.
  10. Broadhead ML, Clark JC, Choong PF, et al. "Making gene therapy for osteosarcoma a reality". Expert Rev Anticancer Ther. 10: 477-80.
  11. Hauben EI, Arends J, Vandenbroucke JP, et al. "Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma", Eur J Hum Genet. 2003; 11: 611-8.
  12. Franchi A, Calzolari A, Zampi G. "Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton". Virchows Arch. 1998; 432: 515-9.
  13. Wu JX, Carpenter PM, Gresens C, et al. "The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas". Oncogene. 1990; 5: 989-1000.
  14. Gamberi G, Benassi MS, Bohling T, et al. "C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression". Oncology. 1998; 55: 556-63.
  15. Shimizu T, Ishikawa T, Sugihara E, et al. "c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis". Oncogene. 29: 5687-99.
  16. Leaner VD, Chick JF, Donninger H, et al. "Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma". Am J Pathol. 2009; 174: 265-75.
  17. Pan KL, Chan WH, Chia YY. "Initial symptoms and delayed diagnosis of osteosarcoma around the knee joint", J Orthop Surg (Hong Kong) 18: 55-7.
  18. W. Brenner, K. H. Bohuslavizki and J. F. Eary, "PET imaging of osteosarcoma". J Nucl Med. 2003; 44: 930-42.
  19. Misaghi A, Goldin A, Awad M, et al. "Osteosarcoma: a comprehensive review". SICOT J. 4: 12.
  20. Thorpe WP, Reilly JJ, Rosenberg SA. "Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy". Cancer. 1979; 43: 2178-81.
  21. Link MP, Goorin AM, Horowitz M, et al. "Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study". Clin Orthop Relat Res. 1991; 8-14.
  22. Bacci G, Longhi A, Ferrari S, et al. "Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: experience at Rizzoli on 1421 patients treated over the last 30 years". Tumori. 2004; 90: 478-84.
  23. Dembla V, Groisberg R, Hess K, et al. "Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors". Sci Rep. 7: 15963.
  24. Groisberg R, Hong DS, Behrang A, et al. "Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials". J Immunother Cancer. 5: 100.
  25. Saraf AJ, Fenger JM, Roberts RD. "Osteosarcoma: Accelerating Progress Makes for a Hopeful Future". Front Oncol. 8: 4.
  26. Hattinger CM, Reverter-Branchat G, Remondini D, et al. "Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques". Eur J Cell Biol. 2003; 82: 483-93.
  27. Flintoff WF, Sadlish H, Gorlick R, et al. "Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas". Biochim Biophys Acta. 2004; 1690: 110-7.
  28. Guo W, Healey JH, Meyers PA, et al. "Mechanisms of methotrexate resistance in osteosarcoma". Clin Cancer Res. 1999; 5: 621-7.
  29. Guo YL, Kang B, Yang LJ, et al. "Tumor necrosis factor-alpha and ceramide induce cell death through different mechanisms in rat mesangial cells". Am J Physiol. 1999; 276: F390-7.
  30. Meyers P Trippett T, Gorlick R, et al. "High dose trimetrexate with leucovorin protection in recurrent childhood malignancies: a phase II trial. " in ASCO Annual Meeting. 1999; 889.
  31. Hattinger CM, Tavanti E, Fanelli M, et al. "Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma". Expert Opin Drug Metab Toxicol. 13: 245-257.
  32. Jackson RC, Fry DW, Boritzki TJ, et al. "Biochemical pharmacology of the lipophilic antifolate, trimetrexate". Adv Enzyme Regul. 1984; 22: 187-206.
  33. Gorlick R, Goker E, Trippett T, et al. "Intrinsic and acquired resistance to methotrexate in acute leukemia". N Engl J Med. 1996; 335: 1041-8.
  34. Park YB, Kim HS, Oh JH, et al. "The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma". Int Orthop. 2001; 24: 307-10.
  35. Safa AR, Stern RK, Choi K, et al. "Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185----Val-185 substitution in P-glycoprotein". Proc Natl Acad Sci U S A. 1990; 87: 7225-9.
  36. Susa M, Iyer AK, Ryu K, et al. "Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma". BMC Cancer. 2009; 9: 399.
  37. Townsend DM, Tew KD. "The role of glutathione-S-transferase in anti-cancer drug resistance". Oncogene. 2003; 22: 7369-75.
  38. Uozaki H, Horiuchi H, Ishida T, et al. "Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis". Cancer. 1997; 79: 2336-44.
  39. Windsor RE, Strauss SJ, Kallis C, et al. "Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study". Cancer. 118: 1856-67.
  40. Pasello M, Manara MC, Michelacci F, et al. "Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy". Anal Cell Pathol (Amst). 34: 131-45.
  41. LeRoith D, Roberts CT, Jr. "The insulin-like growth factor system and cancer". Cancer Lett. 2003; 195: 127-37.
  42. Meric-Bernstam F, Gonzalez-Angulo AM. "Targeting the mTOR signaling network for cancer therapy". J Clin Oncol. 2009; 27: 2278-87.
  43. Zhou Q, Zhu Y, Deng Z, et al, "VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma". Surg Oncol. 20: 13-9.
  44. Gordon IK, Ye F, Kent MS. "Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs". Am J Vet Res. 2008; 69: 1079-84.
  45. Luk F, Yu Y, Walsh WR, et al. "IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines". Cancer Invest. 29: 521-32.
  46. Wan X, Mendoza A, Khanna C, et al. "Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma". Cancer Res. 2005; 65: 2406-11.
  47. Ebb D, Meyers P, Grier H, et al. "Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group". J Clin Oncol. 30: 2545-51.
  48. Maris JM, Courtright J, Houghton PJ, et al. "Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program". Pediatr Blood Cancer. 2008; 50: 581-7.
  49. Wang YH, Xiong J, Wang SF, et al. "Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo". Mol Cell Biochem. 341: 225-33.
  50. Wang Z, Cai H, Lin L, et al. "Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma". Pediatr Blood Cancer. 61: 206-10.
  51. Degenhardt K, Mathew R, Beaudoin B, et al. "Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis". Cancer Cell. 2006; 10: 51-64.
  52. Lambert LA, Qiao N, Hunt KK, et al. "Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model". Cancer Res. 2008; 68: 7966-74.
  53. Kim HJ, Lee SG, Kim YJ, et al. "Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells". Int J Oncol. 42: 1985-92.
  54. Li J, Hou N, Faried A, et al. "Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model". Eur J Cancer. 46: 1900-9.
  55. Zhang Z, Shao Z, Xiong L, et al. "Expression of Beclin1 in osteosarcoma and the effects of down-regulation of autophagy on the chemotherapeutic sensitivity". J Huazhong Univ Sci Technolog Med Sci. 2009; 29: 737-40.
  56. S. P. D'Angelo, W. D. Tap, G. K. Schwartz and R. D. Carvajal, "Sarcoma immunotherapy: past approaches and future directions", Sarcoma 2014: 391967.
  57. Ito H, Murakami K, Yanagawa T, et al. "Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma: case reports", Cancer. 1980; 46: 1562-5.
  58. Edmonson JH, Long HJ, Frytak S, et al. "Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas". Cancer Treat Rep. 1987; 71: 747-8.
  59. Postiglione L, Di Domenico G, Giordano-Lanza G, et al. "Effect of human granulocyte macrophage-colony stimulating factor on differentiation and apoptosis of the human osteosarcoma cell line SaOS-2". Eur J Histochem. 2003; 47: 309-16.
  60. Schwinger W, Klass V, Benesch M, et al. "Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients". Ann Oncol. 2005; 16: 1199-206.
  61. Restifo NP, Dudley ME, Rosenberg SA. "Adoptive immunotherapy for cancer: harnessing the T cell response". Nat Rev Immunol. 12: 269-81.
  62. Ruella M, Kalos M. "Adoptive immunotherapy for cancer", Immunol Rev. 257: 14-38.
  63. Vitale M, Pelusi G, Taroni B, et al. "HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage". Clin Cancer Res. 2005; 11: 67-72.
  64. Ahmed N, Salsman VS, Yvon E, et al. "Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression". Mol Ther. 2009; 17: 1779-87.
  65. Rainusso N, Brawley VS, Ghazi A, et al. "Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma". Cancer Gene Ther. 19: 212-7.
  66. Morgan RA, Yang JC, Kitano M, et al. "Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2". Mol Ther. 18: 843-51.
  67. Raulet DH, Guerra N. "Oncogenic stress sensed by the immune system: role of natural killer cell receptors". Nat Rev Immunol. 2009; 9: 568-80.
  68. Delgado D, Webster DE, DeSantes KB, et al. "KIR receptor-ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cells". Pediatr Blood Cancer. 55: 1300-5.
  69. Bakker AB, Phillips JH, Figdor CG, et al. "Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL". J Immunol. 1998; 160: 5239-45.
  70. Dillman R, Barth N, Selvan S, et al. "Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas". Cancer Biother Radiopharm. 2004; 19: 581-8.
  71. Mackall CL, Rhee EH, Read EJ, et al. "A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas". Clin Cancer Res. 2008; 14: 4850-8.
  72. Wolchok JD, Neyns B, Linette G, et al. "Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study". Lancet Oncol. 11: 155-64.
  73. Yano H, Thakur, A Tomaszewski EN, et al. "Ipilimumab augments antitumor activity of bispecific antibody-armed T cells". J Transl Med. 12: 191.
  74. Iwai Y, Terawaki S, Honjo T. "PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells". Int Immunol. 2005; 17: 133-44.
  75. Okudaira K, Hokari R, Tsuzuki Y, et al. "Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model". Int J Oncol. 2009; 35: 741-9.
  76. Sznol M, Chen L. "Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer", Clin Cancer Res 19: 1021-34.
  77. S. J. Russell, K. W. Peng and J. C. Bell, "Oncolytic virotherapy". Nat Biotechnol. 30: 658-70.
  78. Hingorani P, Sampson V, Lettieri C, et al. "Oncolytic viruses for potential osteosarcoma therapy". Adv Exp Med Biol. 804: 259-83.
  79. Tomko RP, Xu R, Philipson L. "HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses". Proc Natl Acad Sci U S A. 1997; 94: 3352-6.
  80. Bischoff JR, Kirn DH, Williams A, et al. Sampson-Johannes, A. Fattaey and F. McCormick, "An adenovirus mutant that replicates selectively in p53-deficient human tumor cells". Science. 1996; 274: 373-6.
  81. Chu RL, Post DE, Khuri FR, et al. "Use of replicating oncolytic adenoviruses in combination therapy for cancer". Clin Cancer Res. 2004; 10: 5299-312.
  82. Ganly I, Kirn D, Eckhardt G, et al. "A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer". Clin Cancer Res. 2000; 6: 798-806.
  83. Liu S, Dai M, You L, et al. "Advance in herpes simplex viruses for cancer therapy". Sci China Life Sci. 56: 298-305.
  84. Miranda CA, Lima EG, de Lima DB, et al. "Genital infection with herpes simplex virus types 1 and 2 in women from natal, Brazil". ISRN Obstet Gynecol 2014: 323657.
  85. Liu TC, Kirn D. "Viruses with deletions in antiapoptotic genes as potential oncolytic agents". Oncogene. 2005; 24: 6069-79.
  86. Smith KD, Mezhir JJ, Bickenbach K, et al. "Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1". J Virol. 2006; 80: 1110-20.
  87. Bharatan NS, Currier MA, Cripe TP. "Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses". J Pediatr Hematol Oncol. 2002; 24: 447-53.
  88. He S, Li P, Chen CH, et al. "Effective oncolytic vaccinia therapy for human sarcomas". J Surg Res. 175: e53-60.
  89. Hanno GJ. "RNA interference". Nature. 2002; 418: 244-51.
  90. Hayes J, Peruzzi PP, Lawler S. "MicroRNAs in cancer: biomarkers, functions and therapy". Trends Mol Med. 20: 460-9.
  91. Slaby O, Svoboda M, Fabian P, et al. "Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer", Oncology. 2007; 72: 397-402.
  92. Qing Y, Dai N, Cun Y, et al. "miR-513a-5p regulates radiosensitivity of osteosarcoma by targeting human apurinic/apyrimidinic endonuclease". Onco Targets Ther. 2016.
  93. Jiang X, Shan J, Dai N, et al. "Apurinic/apyrimidinic endonuclease 1 regulates angiogenesis in a transforming growth factor beta-dependent manner in human osteosarcoma". Cancer Sci. 106: 1394-401.
  94. Geng S, Gu L, Ju F, et al. "MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1". J Cell Mol Med. 20: 1611-9.
  95. Zhu Z, Tang J, Wang J, et al. "MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells". PLoS One. 11: e0150026.
  96. Lee CC, Putnam AJ, Miranti CK, et al. "Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis". Oncogene. 2004; 23: 5193-202.
  97. Vanas V, Haigl B, Stockhammer V, et al. "MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells". PLoS One. 11: e0161023.
  98. Wei R, Cao G, Deng Z, et al. "miR-140-5p attenuates chemotherapeutic drug-induced cell death by regulating autophagy through inositol 1,4,5-trisphosphate kinase 2 (IP3k2) in human osteosarcoma cells". Biosci Rep. 36.
  99. Lin BC, Huang D, Yu CQ, et al. "MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1". Med Sci Monit. 22: 1761-5.
  100. Zhang Z, Hong Y, Xiang D, et al. "MicroRNA-302/367 cluster governs hESC self-renewal by dually regulating cell cycle and apoptosis pathways". Stem Cell Reports. 4: 645-57.
  101. Cai H, Lin L, Tang M, et al. "Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma". Med Oncol. 30: 499.
  102. Song B, Wang Y, Xi Y, et al. "Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells". Oncogene. 2009; 28: 4065-74.
  103. Santhekadur PK, Das SK, Gredler R, et al. "Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221". J Biol Chem. 287: 13952-8.
  104. Huang X, Ding L, Bennewith KL, et al. "Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation", Mol Cell 35 (2009): 856-67.
  105. Zhang Z, Sun H, Dai H, et al. "MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT". Cell Cycle. 2009; 8: 2756-68.
 

Article Info

  • Journal of Cancer Treatment and Diagnosis
  • Article Type : Mini Review
  • View/Download pdf

Article Notes

  • Published on: April 24, 2018

Keywords

  • Osteosarcoma

  • Chemoresistance
  • Immunotherapy
  • MicroRNAs
  • Pathogenesis

*Correspondence:

Dr. Jessica Cottrell
400 South Orange Ave
South Orange, NJ 07079, USA
Telephone: 973-761-9055
Email: cottreje@shu.edu

© 2018 Cottrell J. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License